How should a chronic non‑productive cough lasting more than eight weeks be managed in an elderly patient (≥65 years) with multiple comorbidities and polypharmacy?

Managing Chronic Dry Cough in the Elderly

In elderly patients with chronic non-productive cough lasting more than 8 weeks, systematically exclude ACE-inhibitor use and smoking first, then pursue empiric sequential trials targeting upper airway cough syndrome, asthma, and gastroesophageal reflux disease—the three conditions that account for over 90% of cases—before considering gabapentin or speech pathology therapy for refractory symptoms. 1, 2

Immediate Red-Flag Exclusion

Before initiating any algorithmic work-up, actively screen for features requiring urgent investigation:

• Hemoptysis, unintentional weight loss, fever, or night sweats mandate immediate chest imaging and specialist referral to exclude malignancy, tuberculosis, or serious infection 1, 2
• New cough in a smoker ≥45 years or any adult aged 55–80 with ≥30 pack-year history requires evaluation for lung cancer 1, 2
• Significant resting or nocturnal dyspnea suggests severe cardiopulmonary disease and warrants urgent assessment 1

Mandatory Baseline Assessment

Medication Review (First Priority)

• Discontinue any ACE-inhibitor immediately—this is the single most common reversible medication cause, affecting 5–50% of users; cough resolves after a median of 26 days (range up to 40 weeks) 1, 2
• Stop sitagliptin if the patient is taking this DPP-4 inhibitor, as it can provoke cough 1, 2

Smoking Status

• Verify current smoking and advise cessation—smoking-related cough typically resolves within 4 weeks after quitting 1
• In elderly patients with substantial smoking history, maintain heightened suspicion for COPD and lung cancer 1

Non-Negotiable Baseline Investigations

• Obtain chest radiograph in every elderly patient with chronic cough to exclude mass lesions, infiltrates, bronchiectasis, interstitial lung disease, and cardiac abnormalities 1, 2
• Perform spirometry with bronchodilator testing to detect obstructive airway disease; normal spirometry does not exclude asthma-related cough 1, 2
• Quantify cough severity using visual-analog scales or validated quality-of-life questionnaires to objectively monitor treatment response 1

Systematic Empiric Treatment Algorithm

The three most common etiologies—upper airway cough syndrome (UACS), asthma, and gastroesophageal reflux disease (GERD)—account for more than 90% of chronic cough cases in adults with normal or near-normal chest radiographs. 1, 2 Up to 67% of patients have multiple simultaneous causes, so partially effective therapies should be retained while adding additional treatments. 1

Step 1: Upper Airway Cough Syndrome (UACS)

• UACS is the single most frequent cause, responsible for 18.6–81.8% of chronic cough 1, 2
• UACS may present without prominent nasal symptoms such as post-nasal drip, making recognition challenging 1
• Initiate first-generation antihistamine-decongestant combination (e.g., brompheniramine + pseudoephedrine) plus intranasal corticosteroid spray 1
• Trial duration: 4–6 weeks before declaring treatment failure 1

Step 2: Asthma (Including Cough-Variant Asthma)

• Asthma accounts for 14.6–41.3% of chronic cough and may present as cough alone without wheeze or dyspnea 1, 2
• Normal spirometry does not exclude asthma; methacholine bronchial provocation testing is advised when spirometry is normal and no obvious etiology is identified 1
• Initiate inhaled corticosteroids according to national asthma guidelines; complete resolution may require up to 8 weeks 1, 3
• A 2-week trial of oral prednisone (30–40 mg daily) helps differentiate eosinophilic airway inflammation; lack of improvement suggests a non-asthmatic cause 1
• For refractory cough-variant asthma, add leukotriene-receptor antagonists rather than long-acting β-agonists 1

Step 3: Gastroesophageal Reflux Disease (GERD)

• GERD contributes to 4.6–85.4% of chronic cough and frequently occurs without gastrointestinal symptoms 1, 2
• Initiate intensive acid suppression with omeprazole 20–40 mg twice daily before meals for ≥3 months (some sources recommend ≥8 weeks), combined with dietary and lifestyle modifications 1
• Clinical response may require 2 weeks to 12 weeks, so adequate trial duration is essential 1
• Remove medications that aggravate reflux (bisphosphonates, nitrates, calcium-channel blockers, theophylline) 1
• Add prokinetic agents (e.g., metoclopramide 10 mg three times daily) if response to PPIs alone is inadequate 1

Step 4: Non-Asthmatic Eosinophilic Bronchitis (NAEB)

• NAEB accounts for 6.4–17.2% of chronic cough and is characterized by eosinophilic airway inflammation without airway hyperresponsiveness or variable airflow obstruction 1, 2
• Inhaled corticosteroids are effective in reducing cough severity in NAEB 1

Follow-Up and Reassessment

• Schedule follow-up within 4–6 weeks to reassess cough severity using validated scales and verify treatment adherence before abandoning a therapeutic trial 1, 3
• Formally quantify treatment response using validated cough-severity instruments rather than relying on subjective patient report 1

Advanced Evaluation for Refractory Cough

If empiric trials targeting UACS, asthma, and GERD fail after adequate duration and adherence is confirmed:

• Obtain high-resolution CT (HRCT) to evaluate for bronchiectasis, interstitial lung disease, or occult masses 1
• Consider bronchoscopy to assess for endobronchial lesions, sarcoidosis, eosinophilic bronchitis, or occult infection 1
• Refer to a specialist cough clinic for comprehensive evaluation before declaring cough "idiopathic" 1

Management of Refractory Chronic Cough

After confirming that the top three diagnoses have been properly treated, multiple etiologies addressed, and ACE-inhibitors/sitagliptin discontinued:

Pharmacologic Options

• Gabapentin is the preferred first-line agent for refractory chronic cough 4, 3
• Dosing schedule: Start at 300 mg once daily and escalate as tolerated up to a maximum of 1,800 mg daily in two divided doses 4, 3
• Discuss potential side effects and risk-benefit profile before initiating, and reassess at 6 months before continuing 4
• The CHEST Cough Expert Panel believes potential benefits in quality of life outweigh side effects in carefully selected patients 4

Non-Pharmacologic Options

• Multimodality speech pathology therapy is suggested as an alternative treatment option for unexplained chronic cough 4
• This approach includes education, cough suppression techniques, breathing exercises, and mindfulness 5

Critical Pitfalls to Avoid in the Elderly

• Assuming a single etiology—up to 67% of patients have multiple concurrent causes requiring combination therapy rather than sequential monotherapy 1, 2
• Inadequate trial duration—empiric therapies must be maintained for 4–6 weeks before declaring failure 1, 3
• Failing to discontinue ACE-inhibitors—this reversible cause must be addressed before extensive work-up 1, 2
• Using acid suppression alone for GERD—comprehensive management including lifestyle modification and dietary changes is necessary 1, 2
• Prescribing inhaled corticosteroids when bronchial hyperresponsiveness and eosinophilia are negative—this approach is not recommended 4
• Prescribing proton pump inhibitors when workup for acid reflux is negative—PPI therapy should not be prescribed in this scenario 4
• Polypharmacy considerations—elderly patients with multiple comorbidities require careful assessment of drug interactions and side-effect burden, particularly when adding gabapentin or other neuromodulators 6